Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype Read more
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Read more
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies Read more
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology Read more
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors Read more
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results Read more
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults Read more